Workflow
ZMC(600216)
icon
Search documents
浙江医药股份有限公司关于召开2024年度业绩说明会的公告
Group 1 - The company will hold an annual performance briefing for 2024 on May 20, 2025, from 9:30 to 10:30 AM [2][4] - The briefing will be conducted via video and online interaction at the Shanghai Stock Exchange Roadshow Center [3][4] - Investors can submit questions from May 13 to May 19, 2025, and the company will address common concerns during the briefing [2][5] Group 2 - Key participants in the briefing will include the company's president, independent directors, and financial director [4] - The company aims to provide a comprehensive understanding of its 2024 operational results and financial status during the briefing [2][3] - After the briefing, investors can access the main content and details through the Shanghai Stock Exchange Roadshow Center [6]
浙江医药(600216) - 浙江医药关于召开2024年度业绩说明会的公告
2025-05-08 09:30
证券代码:600216 证券简称:浙江医药 公告编号:2025-017 浙江医药股份有限公司 关于召开 2024 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 投资者可于 2025 年 5 月 13 日(星期二)至 5 月 19 日(星期一)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 board@zmc-china.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 浙江医药股份有限公司(以下简称"公司")已于 2025 年 4 月 24 日发布公 司 2024 年年度报告,为便于广大投资者更全面深入地了解公司 2024 年度经营成 果、财务状况,公司计划于 2025 年 5 月 20 日(星期二)9:30-10:30 举行 2024 年度业绩说明会,就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以视频结合网络互动召开,公司将针对 2024 年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通,在信息披 ...
今日投资参考:全景运动相机市场空间广阔
Group 1: Market Overview - The three major stock indices experienced narrow fluctuations, with the North Stock 50 Index showing relative strength, while the Shanghai Composite Index fell by 0.05% to 3286.65 points, and the Shenzhen Component Index also dropped by 0.05% to 9849.8 points [1] - The total trading volume in the Shanghai, Shenzhen, and North Stock markets was 10,419 billion, a decrease of 350 billion from the previous day [1] - Sectors such as electricity and insurance declined, while home furnishings, automotive, chemicals, healthcare, agriculture, food and beverage, home appliances, and semiconductors saw gains [1] Group 2: Investment Opportunities in Smart Connected Vehicles - The Ministry of Industry and Information Technology (MIIT) has released key points for automotive standardization by 2025, emphasizing the need to strengthen standards for driving assistance and autonomous driving [2] - CITIC Securities anticipates that companies in the industry chain will focus on improving product maturity and safety, with main manufacturers expected to refine hardware and software architectures [2] - Investment recommendations include leading manufacturers in smart driving development, top suppliers of laser radar, and companies providing testing and simulation services for smart connected vehicles [2] Group 3: Smart Imaging Devices Market - The market for handheld smart imaging devices is projected to reach 36.47 billion in 2023, with a compound annual growth rate (CAGR) of approximately 12.9% from 2023 to 2027, potentially reaching 59.2 billion by 2027 [3] - The panoramic camera market is expected to reach 5 billion, with applications expanding beyond daily life and sports to include video conferencing and robotics [3] - The global market for action cameras is expected to exceed 30 billion in 2023, driven by the rise of outdoor sports [3] Group 4: Vitamin D3 Price Outlook - The price of feed-grade Vitamin D3 is at a historical low, leading to production cuts and supply reductions among some manufacturers [5] - Demand for Vitamin D3 is steadily increasing, with manufacturers reducing output since the beginning of 2024, resulting in historically low inventory levels [5] - Recent price increases have been observed, with significant adjustments in quotes from manufacturers, indicating potential for further price rises [5] Group 5: Consumption Policy and Tax Refunds - The National Taxation Administration has revised the management measures for tax refunds for outbound tourists, simplifying processes and expanding coverage to more small and medium-sized businesses [6] - CITIC Securities estimates that the potential market for tax refunds could reach nearly 100 billion, which may further stimulate consumption and expand domestic demand [6] - Key sectors to watch include traditional retail companies with strong operational capabilities and those involved in consumer infrastructure and travel services [6] Group 6: Electricity Market Developments - The National Development and Reform Commission and the National Energy Administration have announced plans to accelerate the construction of a national electricity spot market, aiming for full coverage by the end of 2025 [8] - Specific timelines have been set for the transition to formal operations in various provinces, with a focus on continuous settlement operations [8] Group 7: Digital Economy Infrastructure - The National Development and Reform Commission is promoting the construction of a national integrated computing network to optimize resource allocation and support the development of the digital economy [9] Group 8: Livestock Production Adjustments - The Ministry of Agriculture and Rural Affairs has issued a plan to adjust and optimize pig production capacity, focusing on monitoring and guiding the market [10]
青蒿素概念下跌0.81%,主力资金净流出8股
Group 1 - The core viewpoint of the news indicates that the Artemisinin concept sector experienced a decline of 0.81%, ranking among the top declines in the concept sector [1] - Within the Artemisinin concept sector, major companies such as Kunming Pharmaceutical Group, New Harmony, and Rundu Co., Ltd. saw significant declines, while companies like Baihua Pharmaceutical, China Resources Sanjiu, and Zhejiang Medicine recorded gains of 1.21%, 0.75%, and 0.75% respectively [1] Group 2 - The financial data shows that the Artemisinin concept sector had a net outflow of 96 million yuan, with eight stocks experiencing net outflows, led by Kunming Pharmaceutical Group with a net outflow of 62.05 million yuan [2] - Other companies with notable net outflows include Rundu Co., Ltd. with 11.84 million yuan, Fosun Pharmaceutical with 9.02 million yuan, and Zhejiang Medicine with 6.48 million yuan [2] - Conversely, the stocks with the highest net inflows included Baihua Pharmaceutical and New Harmony, with net inflows of 6.07 million yuan and 1.19 million yuan respectively [2]
浙江医药(600216):2024年年报、2025年一季报点评:维生素量价齐升,业绩持续高增长
EBSCN· 2025-04-27 08:17
2025 年 4 月 27 日 公司研究 维生素量价齐升,业绩持续高增长 ——浙江医药(600216.SH)2024 年年报&2025 年一季报点评 买入(维持) 当前价:13.66 元 作者 分析师:赵乃迪 执业证书编号:S0930517050005 010-57378026 zhaond@ebscn.com 分析师:蔡嘉豪 执业证书编号:S0930523070003 021-52523800 caijiahao@ebscn.com 市场数据 | 总股本(亿股) | 9.62 | | --- | --- | | 总市值(亿元): | 131.36 | | 一年最低/最高(元): | 9.16/19.40 | | 近 3 月换手率: | 117.62% | 股价相对走势 -10% 19% 49% 78% 108% 04/24 07/24 10/24 01/25 浙江医药 沪深300 | 收益表现 | | | | | --- | --- | --- | --- | | % | 1M | 3M | 1Y | | 相对 | 4.19 | -8.57 | 39.64 | | 绝对 | 0.81 | -9.36 | 4 ...
浙江医药产品涨价首季净利增273% 累计分红43.8亿负债率仅19.5%
Chang Jiang Shang Bao· 2025-04-25 00:43
最新披露的一季报显示,报告期 ,浙江医药实现营业收入22.55亿元,同比微增0.28%;净利润4.09亿 元,同比增长273.08%;扣除非经常性损益的净利润(简称"扣非净利润")4.02亿元,同比增长 279.23%。 扣非净利润与净利润的差距较小,且变动幅度基本一致,说明浙江医药今年前3个月的归母净利润基本 上是来自主营业务。 长江商报消息 主导产品维生素涨价,浙江医药(600216)(600216.SH)业绩增长。 4月23日晚,浙江医药披露的2025年一季度报告显示,前3个月,公司实现营业收入22.55亿元,同比微 增0.28%;归属母公司股东的净利润(以下简称"净利润")4.09亿元,同比增长273.08%。 2024年,公司实现的营业收入接近94亿元,同比增长逾20%;净利润超过11亿元,同比增长约170%。 经营业绩强劲增长的同时,财务状况继续向好。截至一季度末,公司资产负债率仅为19.51%,一季度 的财务费用为-4071.64万元,同比由正转负。 浙江医药持续向股东派发现金红利。数据显示,上市以来,公司累计向股东派发红利43.81亿元。 首季净利倍增 市场行情向好,浙江医药抓住了机会,经营业 ...
浙江医药受益维生素涨价前三月赚4亿元 经营现金流逾3亿元猛增12倍
Chang Jiang Shang Bao· 2025-04-24 09:25
长江商报奔腾新闻记者 沈右荣 维生素涨价,浙江医药(600216.SH)经营业绩继续倍增。 与归母净利润相匹配的是,浙江医药的经营现金流大幅净流入。2024年,公司经营现金流为12.23亿 元,同比增长92.90%。今年第一季度,其经营现金流为3.05亿元,与上年同期的2317.06万元相比,猛 浙江医药主营业务为生命营养品、医药制造类产品及医药商业。生命营养品主要为合成维生素E、维生 素A、天然维生素E、维生素H(生物素)、维生素D3、辅酶Q10等维生素和类维生素产品。公司合成维 生素E,维生素A,天然维生素E,β-胡萝卜素等产品居国际国内前列。 在第一季度报告中,浙江医药解释了归母净利润大幅增长的原因,即公司产品维生素E、维生素A系列 产品销售价格同比上年一季度上涨。 2024年,浙江医药的经营成果也较好。年报显示,公司实现营业收入93.75亿元,创了历史新高,同比 增长20.29%;归母净利润11.61亿元,同比增长170.11%;扣非净利润11.60亿元,同比增长656.77%。 归母净利润、扣非净利润同比倍增的原因,也是主导产品维生素E和维生素A市场价格和需求上升。 2024年,公司维生素及类维生素 ...
浙江医药(600216) - 浙江医药第十届四次监事会决议公告
2025-04-23 09:32
证券代码:600216 证券简称:浙江医药 公告编号:2025-013 浙江医药股份有限公司 第十届四次监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 浙江医药股份有限公司第十届四次监事会会议于 2025 年 4 月 23 日上午在浙 江医药总部 1 号楼 401 会议室召开。本次会议的通知于 2025 年 4 月 3 日以专人 送达或电子邮件方式发出。会议应参加监事五人,实际参加监事五人。会议由监 事会主席李哲先生主持,会议符合《公司法》和《公司章程》的有关规定和要求。 二、监事会会议审议情况 1. 审议通过了《公司 2024 年度监事会工作报告》 同意 5 票,反对 0 票,弃权 0 票。 3.审议通过了《公司 2024 年度利润分配预案》 同意 5 票,反对 0 票,弃权 0 票。 监事会认为,公司 2024 年度利润分配预案的决策程序、利润分配的形式符 合《公司章程》。此利润分配预案充分考虑各方面因素,不存在损害中小股东利 益的情形,符合公司经营现状,有利于公司持续、稳定、 ...
浙江医药(600216) - 浙江医药第十届五次董事会决议公告
2025-04-23 09:31
证券代码:600216 证券简称:浙江医药 公告编号:2025-012 浙江医药股份有限公司 二、会议审议情况 1. 董事会审议通过了《公司 2024 年度董事会工作报告》 同意 11 票,反对 0 票,弃权 0 票。 本议案需提交股东大会审议。 2.董事会审议通过了《公司 2024 年度总裁工作报告》 同意 11 票,反对 0 票,弃权 0 票。 第十届五次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 浙江医药股份有限公司第十届五次董事会会议于 2025年 4 月 23 日上午在浙 江医药总部 1 号楼 401 会议室,以现场结合通讯表决的方式召开。本次会议的通 知于 2025 年 4 月 3 日以专人送达或电子邮件方式发出。会议应参加董事十一人, 实际参加董事十一人,其中董事苍宏宇先生通过通讯表决方式出席会议。会议由 公司董事长李男行先生主持,公司监事及其他高级管理人员列席会议,会议符合 《公司法》和《公司章程》的有关规定和要求。 本议案需提交股东大会审议。 4.董事会审议通 ...
浙江医药(600216) - 浙江医药2024年年度利润分配方案公告
2025-04-23 09:31
浙江医药股份有限公司 证券代码:600216 证券简称:浙江医药 公告编号:2025-014 2024 年年度利润分配方案公告 公司拟向全体股东每股派发现金红利0.37元(含税)。截至2024年12月31 日,公司总股本961,637,750股,以此计算合计拟派发现金红利355,805,967.50 元(含税)。本年度公司现金分红占2024年度归属于上市公司股东净利润的比例 30.66%。 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 每股分配比例:每股派发现金红利 0.37 元(含税) 本次利润分配以实施权益分派股权登记日登记的总股本,扣除回购专 用证券账户中累计回购的股份为基数,具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的,拟维持每股分配比例不 变,相应调整分配总额,并将在相关公告中披露。 不触及《上海证券交易所股票上市规则(2024 年 4 月修订)》(以下简 称《股票上市规则》)第 9.8.1 条第一款第(八)项规定的可能被实施其他风险 警示的情形。 一、 ...